Skip to content
Spontonic· @spontonic · X·· 2026-04-18Score60

pembrolizumab

Reading

MRD / ctDNA / DTP: from detection to treatment decisions

Nivolumab, pembrolizumab and durvalumab sit in this direction not as new drugs, but because perioperative IO trials wrote ctDNA into the stratification.

Body

Gets #CCR8-real tomorrow at #AACR26. "AMG 355 was safe and tolerable at doses up to 700 mg, but clinical activity as a single agent or combined with pembrolizumab was limited." N=30 for pembro plus 355 with one OR. Tox not an issue, efficacy sucks. $AMGN #CHRS

Heat 8 · 6 likes · 2 replies · 0 reposts

Conference abstracts
CT140matched by 药名 ramucirumab
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray

Read the abstract →
CT238NCT02706353matched by 药名 sotigalimab
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study

Salah-Eddine Bentebibel, Daniel J McGrail, Veena Kochat, Emre Arslan, Reham Abdel-Wahab, Sung-Nam Cho, Xiaodong Yang, Daniel H Johnson, Rodabe N Amaria, Isabella C Glitza, Patrick Hwu, Hussein A Tawbi, Jared K Burks, Michael A Davies, Kunal Rai, Suhendan Ekmekcioglu, Adi Diab

Read the abstract →

Source: Spontonic · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org